Genmab A/S (GMAB)

Genmab Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	3,720	3,121	2,390	2,088	1,287
Revenue Growth (YoY)	19.19%	30.59%	14.48%	62.20%	-22.45%
Cost of Revenue	238	143	33	-	-
Gross Profit	3,482	2,978	2,357	-	-
Selling, General & Admin	626	549	478	385.16	196.2
Research & Development	1,606	1,414	1,107	800.55	639.39
Other Operating Expenses	185	43	-	-	-
Total Operating Expenses	2,417	2,006	1,585	1,186	835.59
Operating Income	1,065	972	772	902.02	451.59
Interest Income	408	645	299	459	254.93
Interest Expense	-269	-291	-254	-361.41	-107.35
Total Non-Operating Income (Expense)	139	354	45	97.59	147.57
Pretax Income	1,204	1,326	817	999.61	599.17
Provision for Income Taxes	241	193	186	214.89	146.96
Net Income	963	1,133	631	784.72	452.2
Net Income to Common	963	1,133	631	784.72	452.2
Net Income Growth	-15.00%	79.56%	-19.59%	73.53%	-42.10%
EBIT	1,065	972	772	902.02	451.59

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q